Hemorrhoids Market
Report ID: SQMIG35I3372
Report ID: SQMIG35I3372
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3372 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
148
|Figures:
78
Global Hemorrhoids Market size was valued at USD 5.54 Billion in 2024 and is poised to grow from USD 5.8 Billion in 2025 to USD 8.36 Billion by 2033, growing at a CAGR of 4.68% during the forecast period (2026-2033).
The global hemorrhoids industry includes pharmaceuticals, medical devices, and over‑the‑counter remedies that treat piles, a condition affecting roughly fifteen percent of adults worldwide. Its importance stems from the chronic nature of hemorrhoidal disease, high recurrence rates, and increasing consumer preference for minimally invasive solutions that shorten hospital stays.
Among the drivers shaping the global hemorrhoids market, the expanding geriatric population acts as a catalyst because age‑related vascular degeneration raises hemorrhoidal prevalence, prompting higher demand for therapeutic options. This demographic shift fuels investment in novel device platforms such as cryo‑ablation catheters, which have shown reduced postoperative pain in trials across Europe and Asia. Consequently, manufacturers partner with gastroenterology clinics to launch bundled care pathways that combine colonoscopy with minimally invasive treatment, creating revenue streams beyond drug sales. The synergy between aging demographics, technology adoption, and integrated service models opens sizable significant growth opportunities for established firms and new entrants.
How is AI improving treatment outcomes in the hemorrhoids market?
Artificial Intelligence (AI) is improving treatment outcomes in the hemorrhoids market by enhancing diagnosis accuracy, enabling personalized treatment planning, and supporting minimally invasive procedures. AI-powered imaging and computer vision technologies can assist clinicians in identifying hemorrhoidal severity, differentiating symptoms from other anorectal conditions, and reducing diagnostic variability. By analyzing patient data such as symptoms, medical history, lifestyle factors, and treatment responses, AI-based systems can help physicians recommend more personalized management approaches, including medication, dietary interventions, or procedural treatments.
AI is also supporting the development of advanced digital health platforms that enable remote monitoring of symptoms, treatment adherence, and recovery progress. In clinical settings, AI-assisted tools can improve surgical decision-making by helping specialists select appropriate interventions based on disease grade and patient-specific factors, potentially reducing unnecessary procedures and improving recovery outcomes. Additionally, AI integration with robotic-assisted and image-guided surgical technologies is enhancing precision in hemorrhoid procedures by improving visualization and minimizing tissue damage.
Market snapshot - (2026-2033)
Global Market Size
USD 5.54 Billion
Largest Segment
External Hemorrhoids
Fastest Growth
Internal Hemorrhoids
Growth Rate
4.68% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global hemorrhoids market is segmented by disease type, treatment type, route of administration, distribution channel, end user and region. Based on disease type, the market is segmented into Internal Hemorrhoids, External Hemorrhoids and Mixed Hemorrhoids. Based on treatment type, the market is segmented into Conservative Treatment (Dietary Fiber, Stool Softeners, Lifestyle Modification), Pharmacological Treatment, Minimally Invasive Procedures and Surgical Procedures. Based on route of administration, the market is segmented into Topical, Oral and Injectable. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics and Home Care Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
External hemorrhoids segment dominates with large hemorrhoids market share because patients experience visible symptoms that prompt immediate medical attention, leading clinicians to prioritize diagnosis and treatment. The clear physical manifestations simplify clinical assessment, encouraging early intervention and fostering strong demand for targeted therapies. Moreover, the prevalence of external disease across age groups sustains consistent consumption, reinforcing its central position within the hemorrhoids market ecosystem and drives ongoing product innovation and clinician education.
As per hemorrhoids market outlook, mixed hemorrhoids segment emerges as the most rapidly expanding segment because it combines internal and external symptoms, creating complex clinical needs that spur development of comprehensive treatment regimens. This complexity attracts innovative combination therapies and multidisciplinary management approaches, accelerating market expansion and opening new opportunity pathways for future growth.
Minimally invasive procedures segment leads because they offer effective symptom relief while minimizing patient discomfort, aligning with modern preferences for outpatient care. The ability to perform these interventions under local anesthesia reduces recovery time, encouraging clinicians to adopt them over traditional surgery. This therapeutic advantage strengthens provider confidence, fuels reimbursement support, and drives sustained utilization across diverse patient populations and promotes long‑term adherence to preventive health strategies within clinical practice.
As per hemorrhoids market analysis, pharmacological treatment segment witnesses the strongest growth momentum because novel drug formulations and targeted delivery systems are addressing unmet pain management needs. Continuous pipeline innovation and expanding physician adoption are propelling market penetration, creating opportunities for new entrants and reinforcing overall market expansion in the near term.
To get detailed segments analysis, Request a Free Sample Report
North America shows a synergistic blend of advanced healthcare infrastructure, high consumer awareness, and strong reimbursement frameworks that collectively reinforce market leadership. Robust research ecosystems foster continual innovation in both pharmacologic and minimally invasive therapeutic options, while established distribution networks ensure rapid product accessibility. Physicians benefit from extensive clinical training programs, encouraging adoption of cutting‑edge treatment protocols. Moreover, consumer expectations for quality of life drive demand for effective, convenient care solutions, prompting manufacturers to prioritize North American market needs. This convergence of clinical excellence, regulatory support, and consumer focus creates a self‑reinforcing cycle that sustains the region’s dominant position.
As per hemorrhoids market regional outlook, United States reflects a mature ecosystem where specialty clinics and integrated health systems collaborate closely with device innovators. Clinicians routinely incorporate the latest procedural techniques, supported by comprehensive insurance coverage that eases patient access. Patient education initiatives emphasize early intervention, fostering a proactive treatment culture. Supply chains are optimized for swift delivery of both prescription and over‑the‑counter options, reinforcing market depth and resilience.
As per hemorrhoids market regional forecast, Canada benefits from a publicly funded health system that emphasizes evidence‑based practice and equitable access. Health authorities prioritize cost‑effective therapies, encouraging the adoption of clinically validated treatments. Collaborative networks among provincial health agencies and manufacturers streamline product evaluation and integration. Patient outreach programs raise awareness of preventive measures, supporting early diagnosis and treatment adoption across diverse populations.
Europe’s expansion is propelled by a convergence of heightened health consciousness, supportive regulatory pathways, and a strong tradition of clinical research. Healthcare systems across the region prioritize patient‑centered care, fostering uptake of innovative therapeutic modalities that improve comfort and outcomes. Collaborative research initiatives among leading institutions accelerate the introduction of novel drug formulations and minimally invasive devices. Reimbursement policies increasingly accommodate emerging treatments, while digital health platforms enhance patient education and remote monitoring. Together, these dynamics create a fertile environment for sustained market growth and competitive differentiation among manufacturers.
Germany is characterized by a robust network of academic hospitals and specialist clinics that drive early adoption of advanced therapies. Regulatory agencies maintain rigorous standards that ensure product safety, bolstering clinician confidence. Integrated care pathways streamline treatment decisions, while insurance schemes support reimbursable options, encouraging broader patient access. Industry partnerships with research institutions further catalyze innovation, reinforcing Germany’s leadership role.
United Kingdom experiences accelerated growth through strong public health initiatives and the National Health Service’s focus on evidence‑based interventions. Clinicians benefit from widespread training in contemporary procedural techniques, and funding models increasingly support cost‑effective, high‑quality treatments. Patient education campaigns raise awareness of symptom management, prompting earlier consultation. Collaborative efforts between academia and industry foster rapid translation of research into clinical practice, positioning the United Kingdom as a fast‑moving market.
France is emerging as a dynamic segment driven by a combination of proactive screening programs and growing consumer demand for minimally invasive solutions. Healthcare providers emphasize personalized care plans, supported by reimbursement frameworks that accommodate innovative treatments. Collaborative clinical networks encourage multi‑center studies, enriching the evidence base for new therapies. Patient advocacy groups play an active role in disseminating information, accelerating market uptake within this evolving landscape.
Asia Pacific is enhancing its market presence through rapid urbanization, increasing disposable income, and a cultural shift toward proactive health management. Healthcare systems are expanding capacity, integrating modern diagnostic tools and treatment facilities that broaden therapeutic options. Local manufacturers are investing heavily in research and development, often partnering with global innovators to tailor products for regional preferences. Digital health platforms facilitate widespread education and teleconsultations, reducing barriers to care. Together, these factors are cultivating a more sophisticated market environment that supports ongoing growth and competitive advancement.
Japan reflects a highly organized healthcare delivery model where advanced medical technology is readily incorporated into practice. Physicians prioritize minimally invasive procedures that align with patient expectations for quick recovery. Insurance coverage structures favor clinically proven interventions, encouraging consistent utilization. Ongoing collaboration between academic institutions and device makers accelerates product refinement, reinforcing Japan’s reputation for high‑quality care within the region.
South Korea is propelled by an enthusiastic adoption of innovative therapeutic approaches and a strong emphasis on preventive health. National health policies support the integration of new drug formulations and procedural techniques, while robust digital outreach educates patients on symptom recognition. Clinical centers specialize in rapid diagnosis and treatment, benefiting from close ties with research labs that drive continual product improvement.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Prevalence Among Adults
Advancements In Minimally Invasive Treatments
Limited Awareness of Early Symptoms
Reimbursement Challenges In Emerging Markets
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape is shaped by major pharmaceutical and medical‑device firms intensifying rivalry through strategic acquisitions, joint ventures and technology‑driven product launches; for example, Bausch Health’s acquisition of a niche hemorrhoid‑care portfolio in 2021 accelerated its market share, while Johnson & Johnson partnered with a digital health startup in 2022 to integrate tele‑consultation for hemorrhoid management, and Novartis introduced a novel bio‑adhesive formulation that leverages polymer technology to improve patient outcomes.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global hemorrhoids market growth is propelled primarily by a rising prevalence among adults driven by sedentary lifestyles and poor diet, while a second strong catalyst is the expanding geriatric population that fuels demand for novel minimally invasive technologies. The external hemorrhoids segment remains the largest contributor because visible symptoms prompt immediate medical attention, whereas minimally invasive procedures reshape treatment pathways. North America dominates the market due to advanced healthcare infrastructure, strong reimbursement frameworks and high consumer awareness. However, limited awareness of early symptoms restrains broader adoption by keeping many patients untreated, representing a notable barrier to growth.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 5.54 Billion |
| Market size value in 2033 | USD 1.98 Billion |
| Growth Rate | 4.68% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Hemorrhoids Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Hemorrhoids Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Hemorrhoids Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Hemorrhoids Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Hemorrhoids Market size was valued at USD 5.54 Billion in 2024 and is poised to grow from USD 5.8 Billion in 2025 to USD 1.98 Billion by 2033, growing at a CAGR of 4.68% during the forecast period (2026-2033).
The competitive landscape is shaped by major pharmaceutical and medical‑device firms intensifying rivalry through strategic acquisitions, joint ventures and technology‑driven product launches; for example, Bausch Health’s acquisition of a niche hemorrhoid‑care portfolio in 2021 accelerated its market share, while Johnson & Johnson partnered with a digital health startup in 2022 to integrate tele‑consultation for hemorrhoid management, and Novartis introduced a novel bio‑adhesive formulation that leverages polymer technology to improve patient outcomes. 'Pfizer Inc', 'GlaxoSmithKline plc', 'Johnson & Johnson Services Inc', 'Bayer AG', 'Sanofi SA', 'Novartis AG', 'Teva Pharmaceutical Industries Ltd', 'Viatris Inc', 'Sandoz International GmbH', 'Lupin Limited', 'Cipla Limited', 'Sun Pharmaceutical Industries Ltd', 'Dr Reddys Laboratories Ltd', 'Medtronic plc', 'Cook Medical LLC', 'Boston Scientific Corporation', 'Stryker Corporation', 'Teleflex Incorporated', 'ConMed Corporation', 'AstraZeneca plc'
Rising prevalence among adults is driven by sedentary lifestyles, poor dietary habits, and increased awareness of gastrointestinal health, leading more individuals to seek medical evaluation for discomfort. This heightened patient identification expands the addressable population for therapeutic options, encouraging manufacturers to innovate and broaden product portfolios. As clinicians become more proactive in diagnosing hemorrhoidal conditions, demand for both pharmaceutical and procedural interventions escalates, fostering market expansion through sustained clinical adoption and patient engagement. Consequently, healthcare providers allocate more resources toward preventive screening and treatment pathways, further amplifying market momentum.
Minimally Invasive Technologies Adoption: The shift toward minimally invasive procedures is reshaping treatment pathways for hemorrhoids, as clinicians favor techniques that reduce postoperative discomfort and accelerate recovery. Advanced rubber band ligation devices, laser coagulation systems, and radiofrequency ablation tools are being integrated into outpatient settings, enabling physicians to deliver effective care without hospitalization. This trend is driven by patient preference for quicker return to daily activities and by health‑provider incentives to lower procedural costs while maintaining high therapeutic outcomes and patient satisfaction levels significantly.
Why does North America Dominate the Global Hemorrhoids Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
